Elsevier launches Bioscience Hypotheses – a new journal dedicated to radical ideas in the life sciences
New forum for radical hypotheses on life sciences topics
London, UK, 9 June 2008 – Elsevier, a world-leading publisher of scientific, technical and medical information products and services, is pleased to announce the publication of Bioscience Hypotheses, a new journal for radical hypotheses on topics throughout the life sciences.
The aim of the journal is to stimulate innovation by choosing work that is interesting and challenging, and provides a clear and coherent argument with a testable conclusion. Bioscience Hypotheses is edited by Dr William Bains, biotechnology entrepreneur and innovator, and visiting lecturer at the University of Cambridge.
The journal welcomes papers that:
• deliver new insight into the understanding or application of biology that could be of interest to a wide life science readership
• are clear, coherent, and lay out an argument that is easy to follow
• are not incompatible with known fact (although they may contest the interpretation of those facts)
• provide an interpretation, hypothesis or solution that is testable.
Papers that do not provide a means of testing their conclusion, or differentiating their conclusion from other explanations, will be rejected. Papers that provide some preliminary data (itself perhaps not sufficiently robust to be published as an independent paper, but nevertheless rigorously collected) will be welcomed. However, preliminary data are not a requirement for publication, and Bioscience Hypotheses is not a forum for new experimental results unless they are supporting a broader theoretical structure.
Papers are not subject to standard peer review, but are selected by the Editor on the basis of the criteria laid out above. The journal explicitly does not publish papers addressing medical issues, which should continue to be directed to the sister journal Medical Hypotheses.
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com
+44 20 7424 4392